Class I Histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models

Agriculture & Biology

• kidney neoplasms 77%
• histone deacetylase 62%
• prostatic neoplasms 61%
• immunotherapy 60%
• renal cell carcinoma 49%
• T-lymphocytes 41%
• vaccines 39%
• neoplasms 34%
• interleukin-2 34%
• immunosuppressive agents 17%
• mice 17%
• castration 16%
• acetylation 16%
• dosage 15%
• cytokines 14%
• cell proliferation 13%
• Western blotting 12%
• spleen 12%
• growth retardation 12%
• quantitative polymerase chain reaction 11%
• therapeutics 11%
• protein synthesis 11%
• gene expression 9%
• blood 8%
• assays 8%
• testing 5%
• cells 4%
• methodology 4%

Medicine & Life Sciences

• entinostat 74%
• Histone Deacetylase Inhibitors 53%
• Kidney Neoplasms 50%
• Regulatory T-Lymphocytes 45%
• Immunotherapy 39%
• Prostatic Neoplasms 35%
• Renal Cell Carcinoma 10%
• Interleukin-2 10%
• Down-Regulation 7%
• Combined Vaccines 7%
• Active Immunotherapy 7%
• Neoplasms 7%
• T-Lymphocytes 7%
• Survivin 6%
• Histone Deacetylases 6%
• Castration 6%
• Acetylation 5%
• Immunosuppressive Agents 4%
• Real-Time Polymerase Chain Reaction 4%
• Spleen 4%
• Vaccines 4%
• Western Blotting 3%
• Cell Proliferation 3%
• Cytokines 3%
• Gene Expression 3%
• Growth 2%
• In Vitro Techniques 2%
• Proteins 2%
• Therapeutics 0%

Chemical Compounds

• Entinostat 100%
• Histone 48%
• Dose 9%
• Growth Inhibition 7%
• Effector 7%
• Acetylation 6%
• Antitumor 5%
• Protein 2%
• Time 2%